VFA
COGT icon

Values First Advisors’s Cogent Biosciences COGT Stock Holding History

Values First Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,962
Closed -$32K – 238
2024
Q3 		$32K Buy
+2,962
New +$28.8K 0.02% 252
2023
Q4 		– Sell
-10,318
Closed -$101K – 168
2023
Q3 		$101K Sell
10,318
-6,734
-39% -$79.9K 0.07% 149
2023
Q2 		$202K Buy
17,052
+1,866
+12% +$21.4K 0.12% 146
2023
Q1 		$164K Buy
15,186
+3,644
+32% +$46.6K 0.1% 149
2022
Q4 		$133K Buy
11,542
+530
+5% +$6.57K 0.09% 138
2022
Q3 		$164K Sell
11,012
-5,298
-32% -$72.6K 0.12% 135
2022
Q2 		$147K Buy
+16,310
New +$111K 0.1% 139

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Values First Advisors's COGT Position: Q4 2024 in Review

Values First Advisors sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 2,962 shares — an estimated $32K sold.

Values First Advisors first reported a position in COGT in Q2 2022 and held it in 7 quarters. The position peaked at $202K in Q2 2023. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • Values First Advisors reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • Values First Advisors sold 2,962 Cogent Biosciences shares in Q4 2024, an estimated $32K.
  • Values First Advisors first reported a position in Cogent Biosciences in Q2 2022 and held it in 7 quarters.
  • Values First Advisors's Cogent Biosciences position peaked at $202K in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.